By Jacob Gronholt-Pedersen

COPENHAGEN, DENMARK (Reuters) -Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of its market value in recent weeks.

Novo’s shares rose as much as 5% at opening and were trading 3.5% higher by 0711 GMT.

Three weeks ago, investors wiped $70 billion off its market value, after Novo – which became Europe’s most valuable listed company following the launch of Wegovy in 2021 – issued a profit warning and named a company veteran as new CEO.

On Friday, the U.S. Food and Drug Administration granted accelerated approval for Wegovy to treat metabolic dysfunction-associated steatohepatitis, or MASH, making it the first GLP-1

See Full Page